Copyright
©The Author(s) 2017.
World J Radiol. Sep 28, 2017; 9(9): 350-358
Published online Sep 28, 2017. doi: 10.4329/wjr.v9.i9.350
Published online Sep 28, 2017. doi: 10.4329/wjr.v9.i9.350
Figure 3 High-grade prostate cancer showing no increased uptake on positron emission tomography/computed tomography in a 73-year-old man.
A, B: Prostate MRI performed for raised PSA (19 ng/mL) showed a high probability lesion in the right apex transition zone (arrow in A) with matching restricted diffusion on the ADC map (B). Subsequent targeted transperineal biopsy confirmed Gleason 4 + 5 disease in 40% of cores; C, D: PET/CT performed after a two-month interval and no intervening treatment showed no focal uptake in this region shown as both fused PET/CT imaging (C) and PET alone (D). PET/CT: Positron emission tomography/computed tomography; MRI: Magnetic resonance imaging; ADC: Apparent diffusion co-efficient; PSA: Prostate specific antigen.
- Citation: Chetan MR, Barrett T, Gallagher FA. Clinical significance of prostate 18F-labelled fluorodeoxyglucose uptake on positron emission tomography/computed tomography: A five-year review. World J Radiol 2017; 9(9): 350-358
- URL: https://www.wjgnet.com/1949-8470/full/v9/i9/350.htm
- DOI: https://dx.doi.org/10.4329/wjr.v9.i9.350